Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725309 | 0.85 | KMT2A (0.53) | TSHRLMNASLC6A7ALDH1A1KMT2A | |
| SCHEMBL11078694 | 0.84 | ESR1 (0.54) | ESR1PLAAALPGKDM4EALDH1A1 | |
| SCHEMBL28848047 | 0.84 | ESR1 (0.54) | ESR1PLAAALPGKDM4EALDH1A1 | |
| SCHEMBL11569087 | 0.83 | FDPS (0.47) | ESR1FDPSTSHRRAB9AL3MBTL1 | |
| SCHEMBL10408730 | 0.82 | FDPS (0.51) | FDPSTSHRRAB9AL3MBTL1KDM4E | |
| SCHEMBL10782342 | 0.82 | ESR1 (0.50) | ESR1FDPSL3MBTL1PLAAALPG | |
| SCHEMBL10668273 | 0.81 | ESR1 (0.51) | ESR1PLAAALPGLMNAALDH1A1 | |
| SCHEMBL8013500 | 0.80 | ESR1 (0.44) | ESR1TSHRPLAAALPGKDM4E | |
| SCHEMBL725082 | 0.79 | THRB (0.53) | L3MBTL1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL616402 | 0.79 | ESR1 (0.43) | ESR1TSHRPLAAALPGOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986838-A | Resin composition | 南亚塑胶工业股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-10022356-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022356-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-01-21 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ESR1 1342/4885FDPS 1884/4885TSHR 4440/4885 |
| US-20160015688-A1 | COMPOUNDS FOR TREATMENT OF CANCER | BRAF, NRAS, RAF1 | ESR1 3985/4885FDPS 3163/4885TSHR 2843/4885 |
| US-10022356-B2 | Compounds for treatment of cancer | BRAF, NRAS, RAF1 | ESR1 3985/4885FDPS 3163/4885TSHR 2843/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ESR1 1342/4885FDPS 1884/4885TSHR 4440/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | ESR1 1342/4885FDPS 1884/4885TSHR 4440/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ESR1 1342/4885FDPS 1884/4885TSHR 4440/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | ESR1 1342/4885FDPS 1884/4885TSHR 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.